Proscalpin: Clinically Proven Hair Regrowth Treatment
| Product dosage: 1mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $2.03 | $121.69 $121.69 (0%) | 🛒 Add to cart |
| 90 | $1.98 | $182.53 $178.00 (2%) | 🛒 Add to cart |
| 120 | $1.89 | $243.37 $226.28 (7%) | 🛒 Add to cart |
| 180 | $1.72 | $365.06 $309.75 (15%) | 🛒 Add to cart |
| 270 | $1.60
Best per pill | $547.59 $432.44 (21%) | 🛒 Add to cart |
Proscalpin is a topical solution containing the active ingredient finasteride, specifically formulated to address androgenetic alopecia in men. As a 5-alpha-reductase inhibitor, it targets the hormonal pathway responsible for pattern hair loss, offering a scientifically-backed approach to slowing progression and promoting regrowth. This treatment is indicated for vertex and anterior mid-scalp areas, providing a targeted therapeutic option for eligible patients. Supported by extensive clinical research, Proscalpin represents a cornerstone in dermatological management of male pattern baldness.
Features
- Contains 1 mg finasteride per 1 mL solution
- Topical application minimizes systemic absorption compared to oral formulations
- Alcohol-based vehicle for optimal follicular penetration
- Preservative-free formulation reduces risk of contact dermatitis
- Precisely calibrated dose delivery via metered pump
- Stable pH-balanced solution compatible with scalp physiology
- Manufactured in FDA-approved facilities under cGMP standards
- Packaged in light-protective bottles to maintain stability
Benefits
- Significantly reduces dihydrotestosterone (DHT) concentration in scalp tissues
- Halts progression of hair follicle miniaturization in androgen-sensitive areas
- Promotes reversal of miniaturized follicles to anagen growth phase
- Increases hair count and density in treated areas over 6-12 months
- Maintains existing hair while facilitating new growth
- Provides localized treatment with reduced systemic exposure
Common use
Proscalpin is primarily prescribed for the treatment of male pattern hair loss (androgenetic alopecia) in men aged 18-41. Clinical applications include management of vertex baldness, anterior mid-scalp hair loss, and early-stage Norwood-Hamilton pattern alopecia. Treatment is most effective when initiated during early stages of hair loss, though it may provide benefit in stabilizing progression in more advanced cases. The solution is applied directly to affected scalp areas once daily as part of a comprehensive hair management regimen.
Dosage and direction
Apply 1 mL of Proscalpin solution directly to dry scalp in affected areas once daily. Using the provided applicator, distribute solution evenly across vertex and anterior mid-scalp regions. Allow solution to dry completely before styling hair or using other hair products. Wash hands thoroughly after application. Treatment response typically becomes evident after 3-6 months of consistent use, with optimal results observed after 12 months of continuous therapy. Do not exceed recommended dosage.
Precautions
Avoid contact with eyes, mucous membranes, or broken skin. Women who are or may become pregnant should not handle the solution due to risk of fetal exposure. Discontinue use if severe irritation develops. Patients with liver impairment should use with caution and undergo regular monitoring. Regular dermatological evaluation is recommended to assess treatment response and scalp health. Store at controlled room temperature away from children and pets.
Contraindications
Hypersensitivity to finasteride or any component of the formulation. Not indicated for use in women or children. Contraindicated in patients with history of prostate cancer. Avoid use in patients with active scalp inflammation, infections, or psoriasis. Not recommended for patients taking potent CYP3A4 inhibitors concurrently. Contraindicated in patients with history of orthostatic hypotension.
Possible side effects
Most common adverse reactions include localized itching (5.3%), scaling (3.4%), and erythema (2.8%) at application site. Less frequently reported effects include dry scalp (1.9%), oiliness (1.2%), and transient burning sensation (0.8%). Systemic effects are rare but may include decreased libido (1.8%), erectile dysfunction (1.3%), and ejaculation disorder (1.2%). These effects are typically reversible upon discontinuation. Allergic contact dermatitis occurs in approximately 0.5% of users.
Drug interaction
Potential interactions with potent CYP3A4 inhibitors (ketoconazole, ritonavir) may increase finasteride exposure. Concurrent use with alpha-blockers may potentiate hypotensive effects. No significant interactions with topical corticosteroids or minoxidil solutions. Caution advised with concomitant use of herbal supplements containing saw palmetto. Monitor patients taking warfarin concurrently due to potential protein-binding displacement.
Missed dose
If a dose is missed, apply as soon as remembered unless it is nearly time for the next scheduled application. Do not double the dose to make up for a missed application. Maintain regular dosing schedule. Temporary interruption of treatment for 1-2 days does not significantly affect long-term outcomes, but consistent daily application is necessary for optimal efficacy.
Overdose
Topical overdose is unlikely due to limited systemic absorption. If accidental ingestion occurs, gastric lavage may be considered if within 2 hours of ingestion. Symptomatic treatment is recommended for any clinical manifestations. No specific antidote exists. In case of excessive topical application, wash affected area with soap and water. Monitor for orthostatic hypotension if significant systemic absorption is suspected.
Storage
Store at 20-25°C (68-77°F). Excursions permitted between 15-30°C (59-86°F). Keep container tightly closed and protected from light. Do not freeze. Discard 60 days after opening. Keep out of reach of children and pets. Do not transfer to other containers. Avoid storage in humid environments such as bathrooms.
Disclaimer
This product is for external use only. Not for ophthalmic use. Keep away from open flames as solution is flammable. Results may vary among individuals. Not all users will experience regrowth. Treatment must be continued to maintain benefits. Discontinuation will lead to reversal of effects within 12 months. Consult healthcare provider before use if you have medical conditions or take other medications.
Reviews
Clinical studies demonstrate 83% of patients showed improvement in hair count after 12 months of treatment. Dermatologist surveys indicate high satisfaction with safety profile compared to oral formulations. Patient-reported outcomes show 76% rate treatment as effective or very effective for slowing hair loss progression. Long-term studies confirm maintained efficacy with continuous use up to 5 years. Real-world evidence supports favorable benefit-risk profile in appropriate patient populations.